Advertisement

Topics

The Heart, Diabetes, and Weight Loss Centers of New York Company Profile

15:34 EDT 24th September 2018 | BioPortfolio


News Articles [4587 Associated News Articles listed on BioPortfolio]

Why weight loss produces remission of type 2 diabetes in some patients

A clinical trial recently showed that nearly half of individuals with type 2 diabetes achieved remission to a non-diabetic state after a weight-loss intervention delivered within six years of diagnosi...

Weight loss drug shows no increased risk in cardiovascular outcomes

(Brigham and Women's Hospital) For the first time, investigators report that a weight loss drug led to weight loss without increasing the incidence of heart attacks, strokes and death from heart disea...

This is how losing weight can help stop type-2 diabetes – Hindustan Times

Hindustan TimesThis is how losing weight can help stop type-2 diabetesHindustan TimesLosing weight can lead to an early and sustained improvement in the functioning of pancreatic beta cells, which can...

Weight loss pill Lorcaserin found to have low cardiovascular risk

Weight loss pills have been discovered and then withdrawn from the market because of the risks that they pose to the heart. Some of them have raised the risk of heart attacks, suicides, heart valve pr...

Scientists Discover Why Type-2 Diabetes Can Be Cured by Dramatic Weight Loss – Moneylife

MoneylifeScientists Discover Why Type-2 Diabetes Can Be Cured by Dramatic Weight LossMoneylifeA recent clinical trial (Diabetes Remission Clinical Trial - DiRECT), discovered that nearly half of the p...

Medical News Today: How does weight loss 'fix' type 2 diabetes?

A recent trial has shown that weight loss can send type 2 diabetes into remission. Now, researchers explain why it happens, and why it doesn't always work.

Weight-Loss Drug Belviq Is First to Show No Harm to Heart

MONDAY, Aug. 27, 2018 -- The weight-loss drug Belviq (lorcaserin) appears to help people shed pounds without adversely affecting the heart in those already at higher heart risk, new research shows. Th...

High-energy breakfast leads to better diabetes control and weight loss

In patients with obesity and type 2 diabetes, a meal schedule that includes a high-energy breakfast promotes weight loss, improves diabetes and decreases the need for insulin, new research from Israel...

PubMed Articles [7645 Associated PubMed Articles listed on BioPortfolio]

Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial.

Obesity is present in up to 45% of patients with heart failure (HF). Liraglutide, a glucagon-like peptide-1 (GLP-1) receptor antagonist, facilitates weight loss in obese patients. The efficacy of lira...

Understanding the impact of commonly utilized, non-insulin, glucose-lowering drugs on body weight in patients with type 2 diabetes.

The majority of patients with type 2 diabetes also have obesity. Obesity increases the risk of developing diabetes and is associated with worsened glycemic control and increased morbidity and mortalit...

A weight loss intervention using a commercial mobile application in Latino Americans-Adelgaza Trial.

More than half of Latino adults living in the USA are expected to develop type 2 diabetes in their lifetime. Despite the growing interest in smartphone use for weight loss and diabetes prevention, rel...

Cachexia and sarcopenia in chronic heart failure : Change in muscle strength and muscle structure.

Alterations to the body composition, i.e. the makeup of skeletal muscle, fat and bone density, are frequent in heart insufficiency. Their prevalence and clinical consequences are often underestimated....

CoMET: a protocol for a randomised controlled trial of co-commencement of METformin as an adjunctive treatment to attenuate weight gain and metabolic syndrome in patients with schizophrenia newly commenced on clozapine.

Clozapine, while effective in treatment refractory schizophrenia, is associated with significant weight gain, heart disease and increased risk of type 2 diabetes mellitus (T2DM). Although there is evi...

Clinical Trials [14239 Associated Clinical Trials listed on BioPortfolio]

PowerUp for Health: A Diabetes Prevention Program for Men

The purpose of this two-year proposal is to: 1. develop and 2. complete a pilot test of an adaptation of the evidence-based National Diabetes Prevention Program (NDPP) tai...

Diabetes Interventional Assessment of Slimming or Training to Lessen Inconspicuous Cardiovascular Dysfunction

There is an epidemic of type 2 diabetes in younger adults. These patients are at very high lifetime risk of heart-related complications. Subtle heart abnormalities can be present even at a...

Evaluating Weight Loss Programs for Obese People at Risk for Heart Disease (The POWER Study)

Many people who are obese also have high blood pressure, high cholesterol, or diabetes—all conditions that can increase the risk of heart disease. This study will evaluate two programs t...

Sleep Apnea in Look AHEAD (Action for Health in Diabetes)

This study will assess the effects of weight loss on sleep-disordered breathing (SDB) in 120 obese, type 2 diabetics with obstructive sleep apnea (OSA) from four Look AHEAD sites. Changes ...

BestFIT: a Personalized Weight Loss Program

The purpose of this study is to learn how to personalize weight loss programs. In this research we will study: 1. Whether a weight loss counselor should decide if the traditional weight...

Companies [3266 Associated Companies listed on BioPortfolio]

Heart, Diabetes & Weight Loss Centers of New York

The Heart, Diabetes, and Weight Loss Centers of New York

The Center for Medical Weight Loss

The Center for Medical Weight Loss markets and provides the first national network of medically supervised weight loss centers. The company's 300 centers, located in 43 states, offer customized we...

IntraPace, Inc.

IntraPace was founded in 2001 to address an unmet need in weight loss surgery by developing a gentler solution for weight loss that incorporates essential components of behavior t...

Thinique Medical Weight Loss

Founded in February 2013, Thinique Medical Weight Loss is a physician-supervised weight loss medical franchise that caters to men and women who want to lose weight and transition ...

More Information about "The Heart, Diabetes, and Weight Loss Centers of New York" on BioPortfolio

We have published hundreds of The Heart, Diabetes, and Weight Loss Centers of New York news stories on BioPortfolio along with dozens of The Heart, Diabetes, and Weight Loss Centers of New York Clinical Trials and PubMed Articles about The Heart, Diabetes, and Weight Loss Centers of New York for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of The Heart, Diabetes, and Weight Loss Centers of New York Companies in our database. You can also find out about relevant The Heart, Diabetes, and Weight Loss Centers of New York Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record